These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33263830)

  • 21. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.
    van der Voort A; van der Hoogt KJJ; Wessels R; Schipper RJ; Wesseling J; Sonke GS; Mann RM
    Eur Radiol; 2024 Dec; 34(12):7994-8004. PubMed ID: 38967659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
    Schaefgen B; Mati M; Sinn HP; Golatta M; Stieber A; Rauch G; Hennigs A; Richter H; Domschke C; Schuetz F; Sohn C; Schneeweiss A; Heil J
    Ann Surg Oncol; 2016 Mar; 23(3):789-95. PubMed ID: 26467456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
    Chen JH; Feig B; Agrawal G; Yu H; Carpenter PM; Mehta RS; Nalcioglu O; Su MY
    Cancer; 2008 Jan; 112(1):17-26. PubMed ID: 18000804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
    Groen EJ; van der Noordaa MEM; Schaapveld M; Sonke GS; Mann RM; van Ramshorst MS; Lips EH; Vrancken Peeters MTFD; van Duijnhoven FH; Wesseling J
    Breast Cancer Res Treat; 2021 Aug; 189(1):213-224. PubMed ID: 33945043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study.
    Bitencourt AGV; Pires BS; Calsavara VF; Negrão EMS; Souza JA; Graziano L; Guatelli CS; Makdissi FB; Sanches SM; Tavares MC; Osório CABT; De Brot M; Marques EF; Chojniak R
    Eur Radiol; 2021 Dec; 31(12):9520-9528. PubMed ID: 34036420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
    Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
    JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of multi-parametric breast MR imaging for predicting pathological complete response of operable breast cancer prior to neoadjuvant systemic therapy.
    Tsukada H; Tsukada J; Schrading S; Strobel K; Okamoto T; Kuhl CK
    Magn Reson Imaging; 2019 Oct; 62():242-248. PubMed ID: 31352016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
    Pfob A; Sidey-Gibbons C; Rauch G; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Degenhardt T; Rom J; Rody A; van Mackelenbergh M; Banys-Paluchowski M; Große R; Reinisch M; Karsten M; Golatta M; Heil J
    J Clin Oncol; 2022 Jun; 40(17):1903-1915. PubMed ID: 35108029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
    Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
    Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy.
    Moon HG; Han W; Ahn SK; Cho N; Moon WK; Im SA; Park IA; Noh DY
    Ann Surg; 2013 Jan; 257(1):133-7. PubMed ID: 22968080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
    Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.
    Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS
    Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
    Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status.
    Vugts G; Van den Heuvel F; Maaskant-Braat AJG; Voogd AC; Van Warmerdam LJC; Nieuwenhuijzen GAP; Van der Sangen MJC
    Breast J; 2018 Nov; 24(6):894-901. PubMed ID: 30033607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.
    Peterson JR; Cole JA; Pfeiffer JR; Norris GH; Zhang Y; Lopez-Ramos D; Pandey T; Biancalana M; Esslinger HR; Antony AK; Takiar V
    Breast Cancer Res; 2023 May; 25(1):54. PubMed ID: 37165441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.
    van der Noordaa MEM; Ioan I; Rutgers EJ; van Werkhoven E; Loo CE; Voorthuis R; Wesseling J; van Urk J; Wiersma T; Dezentje V; Vrancken Peeters MTFD; van Duijnhoven FH
    Ann Surg Oncol; 2021 Nov; 28(12):7383-7394. PubMed ID: 33978889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.